RDTCF (Rapid Dose Therapeutics) Cyclically Adjusted Revenue per Share: $0.01 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share?

Rapid Dose Therapeutics RDTCF Cyclically Adjusted Revenue per Share is $0.01 as of Feb. 2026. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rapid Dose Therapeutics's adjusted revenue per share for the three months ended in Feb. 2026 was $0.004. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.01 for the trailing ten years ended in Feb. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-26), Rapid Dose Therapeutics's current stock price is $0.085. Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2026 was $0.01. Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio of today is 8.50.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rapid Dose Therapeutics was 66.00. The lowest was 4.60. And the median was 16.00.


Rapid Dose Therapeutics  (OTCPK:RDTCF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.085/0.01
=8.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rapid Dose Therapeutics was 66.00. The lowest was 4.60. And the median was 16.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Chart

Rapid Dose Therapeutics Annual Data
Trend Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.01 0.01

Rapid Dose Therapeutics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

RDTCF vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio falls into.



Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rapid Dose Therapeutics's adjusted Revenue per Share data for the three months ended in Feb. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=0.004/131.0772*131.0772
=0.004

Current CPI (Feb. 2026) = 131.0772.

Rapid Dose Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201809 0.000 105.636 0.000
201902 0.000 106.268 0.000
201905 0.000 107.927 0.000
201908 0.009 108.085 0.011
201911 -0.009 107.769 -0.011
202002 0.001 108.559 0.001
202005 0.000 107.532 0.000
202008 0.000 108.243 0.000
202011 0.001 108.796 0.001
202102 0.006 109.745 0.007
202105 0.008 111.404 0.009
202108 0.003 112.668 0.003
202111 0.004 113.932 0.005
202202 0.001 115.986 0.001
202205 0.000 120.016 0.000
202208 0.001 120.569 0.001
202211 0.002 121.675 0.002
202302 0.002 122.070 0.002
202305 0.002 124.045 0.002
202308 0.003 125.389 0.003
202311 0.002 125.468 0.002
202402 0.001 125.468 0.001
202405 0.002 127.601 0.002
202408 0.003 127.838 0.003
202411 0.003 127.838 0.003
202502 0.003 128.786 0.003
202505 0.004 129.813 0.004
202508 0.004 130.208 0.004
202511 0.004 130.682 0.004
202602 0.004 131.077 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.01 mean?
Rapid Dose Therapeutics (RDTCF) has a Cyclically Adjusted Revenue per Share of $0.01 as of Feb. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' Cyclically Adjusted Revenue per Share too high?
Rapid Dose Therapeutics' current Cyclically Adjusted Revenue per Share is $0.01.
How does Rapid Dose Therapeutics' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Rapid Dose Therapeutics' Cyclically Adjusted Revenue per Share of $0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current Cyclically Adjusted Revenue per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.25, compared to a current price of $0.09 — trading 66% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Cyclically Adjusted Revenue per Share is $0.01 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.